TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Blood Pressure Response to Exercise Training
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Amount of bone loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Complete Cytogenetic Response (CCyR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: postabsorptive plasma citrulline concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Temporal Artery Temperature
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Axillary Temperature
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference Between Temporal Artery and Rectal Temperatures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference Between Rectal and Axillary Temperatures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Off Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fasting plasma concentration of GI peptides
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Dyspepsia subtype
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Reduction in serum lipids
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Proportion of children discharged from nutritional program as recovered
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Respiratory Distress Syndrome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in Disease Characteristics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of detected circulating DNA RAS mutations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reference values for PiCCO variables
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Non-invasive cardiac output measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Microbiome diversity alterations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Behavioural Dysexecutive Syndrome Inventory
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Liver fatty infiltration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in average intensity of phantom limb pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in frequency of phantom limb pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in duration of phantom limb pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Juniper Mini Asthma Quality of Life Questionnaire (MiniAQLQ) Score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Dyspnoea during arm exercise
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Intraoperative conversion rate
Endpoint domain: Adverse events/effects
Primary endpoint: Postoperative complications (Clavien-Dindo grade II or higher)
Endpoint domain: Adverse events/effects
Primary endpoint: average image quality
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with asthma exacerbation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: changes in laboratory and clinical parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: self-reported heavy drinking
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Intestinal motility
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Intestinal barrier
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in enamel porosity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in cancer-related fatigue functional interference
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Number of patients with cortical osteoporosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Bone and connective tissue outcomes
Primary endpoint: Delirium- and coma-free days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in sputum viscoelasticity (G*)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Adequacy of ablation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Local progression free survival
Endpoint domain: Mortality/survival
Primary endpoint: Gray Matter Volume Biomarkers of 6 Month Prognosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Resting State Functional Connectivity Strength Biomarkers of 6 Month Prognosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Integrity of Specific White Matter Tracts (Fractional Anisotropy) as Measured by DTI Tractography
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Amount of fat within cortical pores at the distal tibia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Amount of vessels within cortical pores at the distal tibia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Association between Type 2 diabetes status and marrow fat at the distal tibia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Area under the time concentration curves from zero to infinity (AUCinf)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in renal pressor response to hyperglycemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in renal pressor response to Angiotensin II
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in serum C-reactive protein levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change From Baseline in Complete 4-domain Mayo Score at Week 10
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concentration of Ixazomib in Tumor Tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Patients With Safety and Tolerability of Ixazomib
Endpoint domain: Adverse events/effects
Primary endpoint: Area under the plasma concentration-time course profile (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total cooperation rate
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Homeostasis Model Assessment Insulin Resistance (HOMA-IR) Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Adaptive Beta-cell Insulin Production
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Distinctive Beta-cell Function From the Arginine Stimulation Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Carbon Monoxide Breath Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Parasitological failure by day 28
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Overall lymphoma response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Safety as assessed using the CTCAE
Endpoint domain: Adverse events/effects
Primary endpoint: Survival rate for 30 days
Endpoint domain: Mortality/survival
Primary endpoint: Occurrence of clinical safety laboratory adverse events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of transition of PERV (Porcine Endogenous Retrovirus)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Male Sexual Health Questionnaire Ejaculation score (MSHQ)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: increase of MFI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: overall incidence of mortality
Endpoint domain: Mortality/survival
Primary endpoint: overall incidence of injuries
Endpoint domain: Adverse events/effects
Primary endpoint: AUC of Prediction performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Epiretinal membrane recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of incidence of Treatment-Emergent Adverse Events including SAEs
Endpoint domain: Adverse events/effects
Primary endpoint: Changes in Frequencies of Peripheral Blood Immune Cell Subsets
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Clinical resolution of hepatitis A disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Appetite Rating
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes in Hormonal Response to Feeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Urea cycle disorder severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Differences in questionnaire responses related to suicidal behavior
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: recurrence of wrist deformity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Curve Within a 28-day Dosing Interval (AUC0-28)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of hospitalized pregnant patients with venous thromboembolism (VTE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: local-regional progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Global patient reported health-related quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in daily frequency of moderate to severe hot flashes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in severity of moderate to severe hot flashes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Survival of pediatric patients
Endpoint domain: Mortality/survival
Primary endpoint: number of patients with success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient function/fitness
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: 3D volumetric changes in soft tissue of the foot
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: changes in bone quality
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detection of EOCs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Rate of breakthrough clinically significant Cytomegalovirus (CMV) infection
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of diagnostic delay
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Observation of Cytomegalovirus (CMV) in Blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Compliance Rate Among Patients With CMV Reactivation
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Plasma concentrations of GW870086X
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: GW870086X pharmacokinetic parameters (AUC, Cmax, t1/2, tmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite of sudden death, cerebrovascular events, coronary events, and renal dysfunction
Endpoint domain: Mortality/survival
Primary endpoint: Investigator's Global Assessment (IGA) score of 0 or 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Test of Infant Motor Performance (TIMP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of modified Borg scale for dyspnea level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Aortic valve regurgitation severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Pain interference with activities
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Mobilization Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood concentrations of glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Blood concentrations of insulin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Blood concentrations of cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change from foot examination questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change from foot care knowledge form
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change from foot self care observation guide
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change from falling questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Blastocyst Evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Decision Quality: Knowledge Subscale
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in Decision Quality: Decision Process Subscale
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Change in Decision Quality: Concordance Subscale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in ISI scores
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Maximum observed concentration (Cmax) of FF, UMEC and VI after single inhaled dose on Day1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the concentration time curve (AUC) between zero and the time to the last measurable concentration (AUC (0-t)) of FF, UMEC and VI after single inhaled dose on Day1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Terminal half-life (t1/2) of FF, UMEC and VI after single inhaled dose on Day1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC(0-7 Days) Based on Antigenic Content
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adequate response defined as no request for supplemental analgesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in ventilator associated pneumonia incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: change in antibiotic resistance pattern
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Insulin secretion during oral stimulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Insulin secretion during iv stimulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Acne Lesion Counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Progression-free Survival at 6-months
Endpoint domain: Mortality/survival
Primary endpoint: Diarrhoea and/or significant gastrointestinal (GI) symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Percentage of Primary Efficacy Responder
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Keratoconus Match Index (KMI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Correlation between SUV and DTI measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Major Adverse Cardiac Events (MACEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Prevalence and Severity of HIV-Associated Neurocognitive Disorder (HAND)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Frequency of HER2(+) circulating tumor cells (CTC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Lung resistance - R(f) changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Lung reactance - X(f) changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in symptom status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postural control on force platform - Static Posturography
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with treatment emergent, treatment-related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: pulmonary exacerbations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Efficacy measured by routine ophthalmological assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Platelet reactivity in response to clopidogrel
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Sensitivity and specificity of serum calprotectin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Unified Parkinson's disease Rating Scale Part III (UPDRS-III)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Single and Dual Task Walking
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Parkinson Anxiety Scale Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of Acute Rejections
Endpoint domain: Adverse events/effects
Primary endpoint: Wound reduction in surface area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to relapse
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Resultant Vector Length
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients with AIDS clinical trials group (ACTG) grade 3 or 4 toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Worsening of Diabetic Kidney Disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Reduction in vasculature
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Changes in transcriptome or proteome expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Mean number of acute serious bacterial infections
Endpoint domain: Adverse events/effects
Primary endpoint: Change in New York Heart Association Functional Classification at 6 months Post-Implant
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Six Minute Hall Walk from Baseline to 6 months Post-Implant
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Left Ventricular Mass Index Change from Baseline to 6 Months Post-Implant
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Modified MacNab criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Head Motion - Extension or Flexion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinically Significant Hypocalcemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Symptom pain on foot
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Health Related Quality of Life - EORTC QLQ-C30
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Disease Specific Quality of Life - EORTC QLQ-BN20
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Occurrence of overdose events
Endpoint domain: Adverse events/effects
Primary endpoint: 7 day quit rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidences of nausea
Endpoint domain: Adverse events/effects
Primary endpoint: incidences of vomiting
Endpoint domain: Adverse events/effects
Primary endpoint: Sensitivity and specificity of the ColoClear screening test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: lung function during rest
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Incidence and character of adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Level and duration of serum viremia and viral shedding
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Immediate therapeutic effects
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Modified NAPSI Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Overall Satisfaction With the Drug Administration Experience
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Injection Duration for the Physiolis Autoinjector
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes